Lurbinectedin Displays Superior Risk/Benefit Ratio Over Topotecan in SCLC
Lurbinectedin demonstrated greater activity and a superior safety profile vs topotecan in a subset of small cell lung cancer.
Phase 3 Atlantis Trial Patients With Small Cell Lung Cancer Chemotherapy Free Interval Central Nervous System Metastases Accelerated Approval From The Fda Alkylating Agent
Source: onclive.com